LISATA THERAPEUTICS (LSTA) Agrees to Reverse Merger With Marea Therapeutics
Lisata will absorb privately held Marea Therapeutics in a stock deal accompanied by a PIPE financing in Series C convertible preferred stock.
Lisata Therapeutics (LSTA) has signed an agreement and plan of merger with privately held Marea Therapeutics, a Delaware biotech, in a transaction that would hand Marea's shareholders newly issued Lisata common and preferred stock. The deal, dated September 17, 2026, was disclosed in an 8-K that also flags a concurrent private placement and changes to Lisata's board and management.
